Nantes, France, April 19, 2011 – TcLand Expression, a leading company focused on gene expression
biomarkers in immunology and personalized medicine today announced the appointment of Felix
Frueh PhD, as new member of the company’s Board of Directors.
"We are particularly honored that a personality like Felix Frueh has agreed to join TcLand Expression's
Board of Directors. Felix is one of the rare worldwide pioneers in personalized medicine and was
instrumental for the development of such discipline during his time at the FDA. He now holds a key
role in Medco, making personalized medicine and companion diagnostics a reality in medical practice.
His vision and in-depth understanding of the market opportunities will highly benefit TcLand
Expression and will be fundamental for achieving our next development milestones", emphasized
Alain Huriez, co-founder and Chief Executive Officer of the company.
"I am delighted to have been appointed as a member of the Board of TcLand. I am impressed by the
scientific excellence of the company and its pioneering developments in the field of companion
diagnostics. The company has all attributes of a worldwide leader in the development of algorithms
critical for treatment decisions in therapeutic areas such as Rheumatoid Arthritis", stated Felix Frueh.
“TcLand Expression is well positioned to have a major, significant and quantifiable impact on patients'
needs in the field of personalized medicine", he concluded.
Felix Frueh is President of Medco Research Institute®, a division of Medco, the largest US Pharmacy
Benefit Manager. In this function, Felix Frueh manages Medco’s expanding peer-reviewed research
initiatives and collaborations in personalized medicine, comparative effectiveness research and
clinical practice improvements, leveraging the newest developments in science to improve the safety
and efficacy of prescription drug care. He is also responsible for the development of Medco’s
Personalized Medicine Research Center, which is under construction in Whitestown, Indiana. Felix
joined Medco in May 2008 to lead the company’s personalized medicine research and development
Prior to joining Medco, Felix Frueh was Associate Director for Genomics at the U.S. Food and Drug
Administration (FDA), where he built and led the core genomics review team in the Center for Drug
Evaluation and Research (CDER), and chaired the first FDA-wide, interdisciplinary pharmacogenomics
review group (IPRG). Prior to the FDA, he was Managing Partner at Stepoutside Consulting, LLC, and
held senior positions at Transgenomic and Protogene Laboratories. Felix Frueh has published
numerous peer-reviewed articles and is a frequent invited speaker at national and international
conferences. He has been a member of various working groups on genetics and genomics at the FDA
and at the Department of Health and Human Services (DHHS), and is a Member of the Board of the
Personalized Medicine Coalition. His academic career includes a faculty appointment at the
Departments of Pharmacology and Medicine at Georgetown University in Washington DC, and
postdoctoral fellowships at Stanford University and the University of Basel, Switzerland, where he
also received his Ph.D. in biochemistry.
About TcLand Expression
TcLand Expression is a recognized pioneer in the discovery, development and validation of gene
expression biomarkers for unmet medical needs in immunology. The company benefits from an
exceptional scientific and clinical environment. For more information, please visit our website:
Alain Huriez, CEO
Phone: +33 2 40 35 89 99
+ 33 6 64 18 99 59
33 1 42 68 86 41